A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).

A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013 Sep; 35(9):1400-11.e1-3.

View in: PubMed

subject areas

Aged
Biological Availability
Cardiovascular Diseases
Cholesterol, HDL
Combined Modality Therapy
Dietary Supplements
Double-Blind Method
Drug Administration Schedule
Drug Therapy, Combination
Fatty Acids, Nonesterified
Fatty Acids, Omega-3
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypertriglyceridemia
Medication Adherence
Middle Aged
Olive Oil
Plant Oils
Risk Factors
Triglycerides

authors with profiles

Michael H. Davidson